Summary

This large phase 3 trial for Alitretinoin results are significant in the this would be the first oral agent specifically for resistant hand dermatitis. the results are positive with good significance. The major problem will be getting the FDA  to accept the drug without the onerous pregnancy prevention programs associated with other retinoids like Accutane, etc. This is why the trial was done in Europe, and not in the US!!

Analysis

It will compare well, in that it has good results, and most patients prefer to take an oral agent, rather than applying a topical agent. The major hurdle will be to get the FDA to approve the drug without the pregnancy prevention program associated with other retinoids.

Sunil Dhawan, MD consults with leading institutions through GLG

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.